|
Last Updated: Jul 13th, 2006 - 10:20:17 |
Aisling Capital today announced that it raised $550 million in equity for its life sciences fund, Aisling Capital II, LP. The ten member Aisling Capital team, which was spun-out of Perseus-Soros Management, LLC, will invest primarily in life science companies that are developing biopharmaceutical products and that are creating businesses based on advanced life science technologies. The Aisling Capital team will continue to participate in the management of the Perseus-Soros BioPharmaceutical Fund, LP and will have a total of $1 billion in committed capital under management.
INFO SOURCES
Aisling Capital
Supporting Material
© Copyright by PEsource
Top of Page
